Preview

Медицинский Совет

Расширенный поиск

Влияние статинов на риск возникновения новых случаев сахарного диабета

https://doi.org/10.21518/2079-701X-2016-3-54-57

Полный текст:

Аннотация

В последние годы в литературе появляются данные об увеличении риска возникновения новых случаев СД на фоне приема статинов. В обзоре рассматриваются исследования последних лет, посвященные данной проблеме, возможные механизмы нарушения метаболизма глюкозы на фоне терапии статинами. Анализируются целевые уровни атерогенных липидов у пациентов с СД и метаболическим синдромом.

Об авторах

С. В. Шалаев
Тюменский государственный медицинский университет; Областная клиническая больница №1
Россия


З. М. Сафиуллина
Тюменский государственный медицинский университет; Областная клиническая больница №1
Россия


Список литературы

1. Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, Caputo S, Grzesk G, Kubica A, Swiatkiewicz I, Sukiennik A, Kelm M, De Servi S, Kubica J. Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. Am J Cardiol, 2013 Jan 24. pii: S0002-9149(12)02640-9. doi: 10.1016/j. amjcard.2012.12.037. [Epub ahead of print].

2. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett, 2001, 507(3): 357-61.

3. Драпкина О.М. Статины и риск развития сахарного диабета. Рациональная Фармакотерапия в Кардиологии, 2013, 9(4): 444-447.

4. Драпкина О.М. Статины и сахарный диабет: риск и польза. Кардиоваскулярная терапия и профилактика, 2012, 11(6): 85-90.

5. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006, 368: 1155-63.

6. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002, 360: 1623-30.

7. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multi-center randomised controlled trial. Lancet, 2003, 361: 1149-58.

8. Sukhija R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med, 2009, 57: 495-499.

9. Preiss D, Sreenivasa Rao Kondapally Seshasai, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter Ph, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ P, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis. JAMA, 2011, 305(24): 2556-2564.

10. Culver A, Ockene I, Balasubramanian R, Olendzki B, Sepavich D, Wactawski-Wende J et al. Statin use and risk of diabetes mellitus in postmeno-pausal women in the Women's Health Initiative. Arch Intern Med, 2012, 172: 144-152.

11. Swapnil N. Rajpathak, Dharam J. Kumbhani, Jill Crandall et al. Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis. Diabetes Care, 2009, 32(10): 1924-9.

12. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 2010, 375(9716): 735-42.

13. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008, 359: 2195-2207.

14. Waters DD. Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. Results From 3 Large Randomized Clinical Trials. JACC, 2011, 57: 1535-1545.

15. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 2001, 103: 357-62.

16. Rautio N, Jokelainen J, Oksa H, et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open, 2012, 2: e001472. doi:10.1136/bmjo-pen-2012-001472.

17. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366: 1267-78.

18. Drapkina O.M. Statins and the risk of developing diabetes. Ratsionalnaya Farmakoterapiya v Kardiologii, 2013, 9 (4): 444-447.

19. Drapkina O.M. Statins and Diabetes Mellitus: risks and benefits. Kardiovaskulyarnaya Terapiya i Profilaktika, 2012, 11(6): 85-90.

20. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (V пересмотр). Москва, 2012 год.

21. Diagnosis and management of lipidosis for the prevention and treatment of atherosclerosis. Russian guidelines (V revision). Moscow, 2012.

22. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010, 376: 1670-81.

23. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 2008, 371: 117-25.

24. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002, 346: 393-403.

25. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract, 2005, 67: 152-62.

26. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care, 1997, 20: 537-44.

27. Ramachandran A, Snehalatha C, Mary S et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia, 2006, 49: 289-97.

28. Tuomilehto J, Lindstrцm J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 2001, 344: 1343-50.

29. Simsek S, Schalkwijk CG, Wolffenbuttel BH. Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes-the CORALL study. Diabet Med, 2012, 29: 628-631.

30. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol, 2011, 26: 342-347.

31. Baker WL, Talati R, White CM et al. Differing effect of statins on insulin sensitivity in nondiabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract, 2010, 87: 98-107.

32. Jula A, Marniemi J, Huupponen R et al. Effects of diet and simvastatin on serum lipids, insulin and antioxidants in hypercholesterolemic men. A randomized controlled trial. JAMA, 2002, 287: 598--605.

33. Ohrvall M, Lithell H, Johansson J et al. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin dependent diabetes mellitus and hyperlipoproteinemia. Metabolism, 1995, 44: 212-217.

34. Stewart MW, Dyer RG, Alberti KG, et al. The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidemia. Diabet Med., 1995, 12: 250-257.

35. Hwu CM, Kwok CF, Chen HS et al. Lack of effects of simvastatin on insulin sensitivity in type 2 diabetic patients with hypercholesterolemia: results from a double-blind, randomized, placebo-controlled crossover study. Diabet Med., 1999, 16: 749-754.

36. Paolisso G, Barbagallo M, Petrella G, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis, 2000, 150: 121-127.

37. Koh KK, Quon MJ, Han SH et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis, 2009, 204(2): 483-490.

38. Nathan DM, Buse JB, Davidson MB et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Clinical Diabetes, 2009, 27(1): 4-16.

39. Wang K, Liu C, Chao T, Huang C, Wu C, Chen S et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol, 2012, 60: 1231-1238.

40. EAS / ESC Guidelines for the management of dyslipidemias. Eur Heart J, 2011, 32: 1769- 1818.


Просмотров: 173


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)